| A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of | Bad Bentheim, Dresden, Frankfurt am Main | Phase II | rekrutiert |
| A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Par | Bad Bentheim, Hamburg | Phase II | rekrutiert |
| A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis | Heidelberg, Tübingen, Augsburg | Phase II | rekrutiert |
| A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Mod | Münster, Dresden | Phase III | rekrutiert |
| A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermati | Bad Bentheim, Dresden, Frankfurt am Main | Phase II | rekrutiert |
| A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Mode | Bad Bentheim, Mainz, Magdeburg | Phase II | rekrutiert |
| A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to S | Erlangen, Bad Bentheim, Münster | Phase III | rekrutiert |
| A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 | Berlin | Phase I | rekrutiert |
| A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticos | Buxtehude, Dresden, Mainz | Phase III | rekrutiert |
| Determinants of Chronic Inflammatory Skin Disease Trajectories | Kiel | — | rekrutiert |
| Disease Trajectories and Anti-cytokine Response Signatures in Atopic Dermatitis and Psoriasis | Kiel | — | rekrutiert |
| Extrinsic and Intrinsic Factors in Atopic Dermatitis Upon Systemic Immune Modulation | Berlin | — | rekrutiert |
| Lebrikizumab in Moderate-to-severe Atopic Dermatitis | Freiburg im Breisgau | Phase IV | rekrutiert |
| Microbiome in Atopic Dermatitis Under Systemic Therapy | Berlin | — | rekrutiert |
| Molecular Signatures in Inflammatory Skin Disease | Kiel | — | rekrutiert |
| Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients Wi | Frankfurt am Main, Mainz, Bad Bentheim | Phase II | rekrutiert |
| Real-world Effectiveness Study of Long-term Treatment With Dupilumab in Participants ≥6 Years Wi | Aachen, Ahaus, Andernach | — | rekrutiert |
| Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis | Karlsruhe, Langenau, Augsburg | — | rekrutiert |
| Replication of the Heads Up Atopic Dermatitis Trial With Registry Data | Dresden | — | rekrutiert |